Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party

Postibrutinib outcomes in patients with mantle cell lymphoma

(2016) P. Martin et al.   BLOOD

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

(2016) Christian W. Eskelund et al.   BRITISH JOURNAL OF HAEMATOLOGY

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

(2016) Martin Dreyling et al.   LANCET

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

(2016) Olivier Hermine et al.   LANCET

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

(2015) M. L. Wang et al.   BLOOD

ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma

(2013) M. Dreyling et al.   ANNALS OF ONCOLOGY

Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research

(2013) Mehdi Hamadani et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation Timing and Modality

(2013) Timothy S. Fenske et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience

(2012) S. Le Gouill et al.   ANNALS OF ONCOLOGY

CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte

(2012) R. Delarue et al.   BLOOD

Guidelines for the investigation and management of mantle cell lymphoma

(2012) P. McKay et al.   BRITISH JOURNAL OF HAEMATOLOGY

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur

(2012) Christian H. Geisler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study of the British Society for Blood and Marrow Transplantation

(2010) Gordon Cook et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

(2010) R. Chakraverty et al.   BLOOD

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma

(2009) C. S. Tam et al.   BLOOD

Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909

(2009) Lloyd E. Damon et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

(2008) C. H. Geisler et al.   BLOOD